Obseva

nature meets nurture

Focused on unmet needs in women's reproductive health

SVB Leerink 10th Annual Global Healthcare Conference

Product overview

YSELTY® (LINZAGOLIX)

Potential to relieve symptoms of heavy menstrual bleeding due to uterine fibroids and pain associated with endometriosis

EBOPIPRANT (OBE022)

Potential to delay preterm birth to improve newborn health and reduce medical costs

NOLASIBAN



Potential to improve live birth rate following IVF & embryo transfer

Multiple development programs drive value

	Phase 1	Phase 2	Phase 3	Next Milestones
YSELTY® (LINZAGOLIX) Oral GnRH receptor antagonist	Uterine Fibroids – Ph3 PRIMROSE 2 (EU & US)			NDA submission (Q2:21) MAA for uterine fibroids expected approval (Q4:21)
	Uterine Fibroids – Ph3 PRIMROSE 1 (US)			
	Endometriosis – Ph3 EDELWEISS 3 (EU & US)			EDELWEISS 3: Primary endpoint readout expected (Q4:21)
EBOPIPRANT Oral $PGF_{2\alpha}$ receptor antagonist	Preterm Labor – Ph2b (EU & Asia)			Initiation of Phase 2b dose ranging study (Q4:21)
NOLASIBAN Oral oxytocin receptor antagonist	IVF – Ph1/2 (China)			In development, partnership with Yuyuan BioScience Technology (PRC)

Ebopiprant, a potential breakthrough for preterm labor*

Over 50% reduction of singleton delivery within 48 hrs

Enabling administration of critical drugs for neonatal protection

Favorable maternal, fetal and neonatal safety

Maternal, fetal and neonatal safety comparable to placebo

Supports advancing ebopiprant into Phase 2b

Phase 2b study will include higher doses to more fully define ebopiprant potential and the longer-term benefits for babies

Ebopiprant has demonstrated proof of concept in delaying preterm birth, enabling ObsEva to plan its further development

ObsEva

** on top a Standard of care Atosiban*

Potential new gold standard treatment for uterine fibroids, designed to treat more women

Potentially best-in-class

Unique PD/PK Profile

Efficacy sustained up to 52 weeks for all dose regimens

Favorable tolerability profile

No safety signal of concern

BMD remains within normal ranges during and after treatment

Unique set of treatment options

Unique low dose option without ABT

Significant uterine volume reduction for 200 mg without ABT

ABT[1] containing regimens may be contraindicated in up to 50% of US women with uterine fibroids based on the elagolix US label[2] and analysis of CDC data[3]

[1] ABT = estradiol 1mg/norethindrone acetate 0.5mg
[2] U.S. FDA elagolix PI, section 4. Contraindications and section 5.1. Warnings and precautions – thromboembolic disorders and vascular events
[3] Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#nation; https://www.cdc.gov/2018

DISCLAIMER: YSELTY is still not approved for use in the US

Investor highlights

1. Pursuing promising large indications for serious conditions that compromise **women's reproductive health and beyond**, with the potential to extend into other indications including prostate cancer
2. Ebopiprant, the **only known product in development for preterm labor, has positive Phase 2a data** that support a **Phase 2b dose ranging study**
3. Yselty® has potential **best in class efficacy, a favorable tolerability profile, and unique flexible dosing options**
4. Business model built on strong **global partnerships and collaborations**
5. Seasoned **leadership team** with a track record for success